Browse by Series:

FDA Approvals in CLL and ALL, NDA Accepted in Melanoma, and More

Gina Columbus
Published: Thursday, Sep 08, 2016



Gina Columbus reports on FDA approvals for blinatumomab in acute lymphoblastic leukemia and ofatumumab in chronic lymphocytic leukemia, encouraging phase III findings with atezolizumab in lung cancer, acceptance of a new drug application for binimetinib in melanoma, and a European approval for crizotinib in lung cancer.
SELECTED
LANGUAGE
Slider Left
Slider Right


Gina Columbus reports on FDA approvals for blinatumomab in acute lymphoblastic leukemia and ofatumumab in chronic lymphocytic leukemia, encouraging phase III findings with atezolizumab in lung cancer, acceptance of a new drug application for binimetinib in melanoma, and a European approval for crizotinib in lung cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x